Evidence map›Paper›PMID 34629887›Full record

ArticleThe application of clinical genetics2021

Genetic Profile of the Dystrophin Gene Reveals New Mutations in Colombian Patients Affected with Muscular Dystrophinopathy.

Paula Triana-Fonseca, Juan Fernando Parada-Márquez, Claudia T Silva-Aldana, Daniela Zambrano-Arenas, Laura Lucia Arias-Gomez, Natalia Morales-Fonseca, Esteban Medina-Méndez, Carlos M Restrepo, Daniel Felipe Silgado-Guzmán, Dora Janeth Fonseca-Mendoza

Open access · goldAbstract read
In one paragraph

Article in The application of clinical genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Molecular genetics of dystrophinopathy.Journal of human genetics · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Paula Triana-FonsecaFacultad de Medicina, Universidad del Bosque, Bogotá, DC, Colombia.ORCID 0000-0001-9877-1396
Juan Fernando Parada-MárquezFacultad de Medicina, Universidad del Bosque, Bogotá, DC, Colombia.ORCID 0000-0002-1101-3670
Claudia T Silva-AldanaDepartment of Molecular Diagnosis, Genética Molecular de Colombia SAS, Bogotá, DC, Colombia.ORCID 0000-0001-8172-5860
Daniela Zambrano-ArenasFacultad de Medicina, Universidad del Bosque, Bogotá, DC, Colombia.
Laura Lucia Arias-GomezDepartment of Molecular Diagnosis, Genética Molecular de Colombia SAS, Bogotá, DC, Colombia.
Natalia Morales-FonsecaDepartment of Medicine, Instituto Colombiano de Neurociencias, Bogotá, DC, Colombia.
Esteban Medina-MéndezDepartment of Molecular Diagnosis, Genética Molecular de Colombia SAS, Bogotá, DC, Colombia.
Carlos M RestrepoCenter for Research in Genetics and Genomics - CIGGUR, GENIUROS Research Group, School of Medicine and Health Sciences, Universidad Del Rosario, Bogotá, DC, Colombia.ORCID 0000-0001-6410-0084
Daniel Felipe Silgado-GuzmánDepartment of Molecular Diagnosis, Genética Molecular de Colombia SAS, Bogotá, DC, Colombia.ORCID 0000-0002-7528-4816
Dora Janeth Fonseca-MendozaCenter for Research in Genetics and Genomics - CIGGUR, GENIUROS Research Group, School of Medicine and Health Sciences, Universidad Del Rosario, Bogotá, DC, Colombia.ORCID 0000-0002-7323-6570
Universidad El Bosque · COUniversidad del Rosario · COInstituto Neurológico de Colombia · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuchenne and Becker muscular dystrophies (DMD/BMD) are the most common human dystrophinopathies with recessive X-linked inheritance. Dystrophin gene deletions and duplications are the most common mutations, followed by point mutations. The aim of this study is to characterize the mutational profile of the dystrophin gene in Colombian patients with DMD/BMD. MATERIAL AND

methodsMutational profiling was determined in 69 affected patients using Sanger sequencing, next-generation sequencing (NGS) and/or multiplex ligation dependent-probes amplification (MLPA). Genetic variants were classified according to molecular consequence and new variants were determined through database and literature analysis.

resultsMutational profile in affected patients revealed that large deletions/duplications analyzed by MLPA accounted for 72.5% of all genetic variations. By using Sanger sequencing or NGS, we identified point mutations in 15.9% and small deletions in 11.6% of the patients. New mutations were found, most of them were point mutations or small deletions (10.1%).

conclusionOur results described the genetic profile of the dystrophin gene in Colombian patients with DMD and contribute to efforts to identify molecular variants in Latin American populations. For our population, 18.8% of cases could be treated with FDA or MDA approved molecular therapies based on specific mutations. These data contribute to the establishment of appropriate genetic counseling and potential treatment.

Indexed as

DMDDuchenne–Becker muscular dystrophyexon skippingMLPAmutationnext-generation sequencingtarget molecular therapy

Identifiers

PMID34629887
PMCPMC8493106
OpenAlexW3202942380

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.